天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

ChemicalBook >> journal list >> International Journal of Molecular Sciences >>article
International Journal of Molecular Sciences

International Journal of Molecular Sciences

IF: 5.59
Download PDF

The Latest Evidence of Erythropoietin in the Treatment of Glaucoma.

Published:16 December 2022 DOI: 10.3390/ijms232416038 PMID: 36555679
Ting-Yi Lin, Yi-Fen Lai, Yi-Hao Chen, Da-Wen Lu

Abstract

Erythropoietin (EPO) is a circulating hormone conventionally considered to be responsible for erythropoiesis. In addition to facilitating red blood cell production, EPO has pluripotent potential, such as for cognition improvement, neurogenesis, and anti-fibrotic, anti-apoptotic, anti-oxidative, and anti-inflammatory effects. In human retinal tissues, EPO receptors (EPORs) are expressed in the photoreceptor cells, retinal pigment epithelium, and retinal ganglion cell layer. Studies have suggested its potential therapeutic effects in many neurodegenerative diseases, including glaucoma. In this review, we discuss the correlation between glaucoma and EPO, physiology and potential neuroprotective function of the EPO/EPOR system, and latest evidence for the treatment of glaucoma with EPO.

Substances (2)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Erythropoietin 11096-26-7 C22H22ClKN6O 103 suppliers $75.00-$950.00
EPO 39 suppliers $366.00-$1258.00

Similar articles

IF:5.9

Benzalkonium Chloride in Glaucoma Medications

Ocular Surface Robert Noecker MD, MBA ,etc Published: 1 July 2011
IF:8.3

Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis.

ACS Applied Materials & Interfaces Camille Keenan, Kim E Nichols,etc Published: 16 February 2021
IF:13

Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

Drugs Susan J Keam, Katherine F Croom,etc Published: 1 January 2005